XML 43 R29.htm IDEA: XBRL DOCUMENT
v3.25.2

Segment and Geographic Data (Tables) | 6 Months Ended
--- | ---
Jun. 30, 2025
Segment Reporting [Abstract] |
Reconciliation of Operating Profit (Loss) from Segments to Consolidated |
Segment Results |  |  |  |  |  |  |
| Three Months |  | Six Months
| 2025 |  | 2024 |  | 2025 |  | 2024
MedSurg and Neurotechnology | $3,771 |  | $3,215 |  | $7,282 |  | $6,312
Orthopaedics | 2,251 |  | 2,207 |  | 4,606 |  | 4,353
Net sales | $6,022 |  | $5,422 |  | $11,888 |  | $10,665
MedSurg and Neurotechnology | $1,414 |  | $1,287 |  | $2,736 |  | $2,525
Orthopaedics | 599 |  | 576 |  | 1,228 |  | 1,167
Cost of sales | $2,013 |  | $1,863 |  | $3,964 |  | $3,692
MedSurg and Neurotechnology | $246 |  | $194 |  | $471 |  | $389
Orthopaedics | 127 |  | 136 |  | 267 |  | 270
Segment research, development and engineering expenses | $373 |  | $330 |  | $738 |  | $659
MedSurg and Neurotechnology | $984 |  | $775 |  | $1,921 |  | $1,538
Orthopaedics | 743 |  | 756 |  | 1,590 |  | 1,507
Segment selling, general and administrative expenses | $1,727 |  | $1,531 |  | $3,511 |  | $3,045
MedSurg and Neurotechnology | $58 |  | $56 |  | $115 |  | $110
Orthopaedics | 104 |  | 105 |  | 202 |  | 213
Segment depreciation and amortization | $162 |  | $161 |  | $317 |  | $323
Corporate and Other | $40 |  | $38 |  | $79 |  | $78
Amortization of intangible assets | 187 |  | 155 |  | 354 |  | 308
Total depreciation and amortization | $389 |  | $354 |  | $750 |  | $709
MedSurg and Neurotechnology | $1,069 |  | $903 |  | $2,039 |  | $1,750
Orthopaedics | 678 |  | 634 |  | 1,319 |  | 1,196
Segment operating income | $1,747 |  | $1,537 |  | $3,358 |  | $2,946
Items not allocated to segments: |  |  |  |  |  |  |
Corporate and Other | $(202) |  | $(203) |  | $(469) |  | $(466)
Inventory stepped up to fair value | (65) |  | (9) |  | (99) |  | (9)
Acquisition and integration-related charges | (78) |  | (14) |  | (263) |  | (1)
Amortization of intangible assets | (187) |  | (155) |  | (354) |  | (308)
Structural optimization and other special charges | (11) |  | (59) |  | (52) |  | (70)
Goodwill and other impairments | (55) |  | (16) |  | (90) |  | (19)
Medical device regulation | (7) |  | (15) |  | (19) |  | (28)
Recall-related matters | (22) |  | (17) |  | (55) |  | (22)
Regulatory and legal matters | (7) |  | 2 |  | (7) |  | —
Consolidated operating income | $1,113 |  | $1,051 |  | $1,950 |  | $2,023
Segment Assets |  |
| June 30 |  | December 31
| 2025 |  | 2024
Assets: |  |  |
MedSurg and Neurotechnology | $26,909 |  | $23,115
Orthopaedics | 17,865 |  | 18,507
Total segment assets | $44,774 |  | $41,622
Corporate and Other | 1,557 |  | 1,349
Total assets | $46,331 |  | $42,971
Sales and Other Financial Information by Business Segment |
Segment Capital Spending | Six Months
| 2025 |  | 2024
Purchases of property, plant and equipment: |  |  |
MedSurg and Neurotechnology | $95 |  | $83
Orthopaedics | 101 |  | 111
Total segment purchases of property, plant and equipment | $196 |  | $194
Corporate and Other | 110 |  | 125
Total purchases of property, plant and equipment | $306 |  | $319

X
- Definition Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details
Name: | us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details
Name: | us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration